



Chinook Therapeutics

Changing the Course of Kidney Care

ASN Kidney Week 2022 Investor Presentation

November 4, 2022

©2022 Chinook Therapeutics. All Rights Reserved.

Note Regarding Forward-Looking Statements

Certain of the statements made in this presentation are forward looking, including those relating to Chinook's business, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of initiation and results of clinical trials and sufficiency of its cash resources. In some cases, you can identify these statements by forward-looking words such as "may," "will," "continue," "anticipate," "intend," "could," "project," "expect" or the negative or plural of these words or similar expressions. Forwardlooking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that may be more advanced or have greater resources than we do, our ability to obtain and adequately protect intellectual property rights for our product candidates and the effects of COVID-19 on our clinical programs and business operations. Many of these risks are described in greater detail in our filings with the SEC. Any forward-looking statements in this presentation speak only as of the date hereof. Chinook assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this presentation.



Today's Presenters



Eric Dobmeier President & CEO



Andrew King, DVM, PhD Chief Scientific Officer



Charlotte Jones-Burton, MD, MS SVP, Product Development & Strategy



Sreedhar A. Mandayam, MD, MPH, MBA, FASN

Professor of Nephrology at the University of Texas

MD Anderson Cancer Center and Baylor College of

Medicine

Laura Kooienga, MD Practicing Nephrologist and Director of Research at Colorado Kidney Care







Opening Remarks



Introduction		Eric Dobmeier
TH-PO497	Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study	Du Sucadhau A Mandayana
FR-PO659	Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy	Dr. Sreedhar A. Mandayam
BION-1301	PI Perspective	Dr. Laura Kooienga
FR-PO334	Preclinical Efficacy of CHK-336: A First in Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for The Treatment of Primary Hyperoxalurias	
TH-PO419	Single Nuclei RNA-seq Reveals Cell-type Specific Responses to Disease and Enalapril in the gddY Mouse Model of IgAN	Dr. Andrew King
FR-OR60	A Multi-Omics Approach to IgA Nephropathy Characterization in the NURTuRE Cohort Enables Precision-Based Treatment Approaches	
Atrasentan Program Update		Du Charlatta Iana Dantan
BION-1301 Program Update		Dr. Charlotte Jones-Burton
Closing		Eric Dobmeier
Q&A		







AFFI

Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study

Anjay Rastogi¹, Michelle N. Rheault², Sung Gyun Kim³, Nam D. Vo⁴, Dwarakanathan Ranganathan⁵, Lesley A. Inker⁶, David K. Packham⁷, Mark Vishnepolsky⁸, Khushboo Sheth⁹, Todd DeVries⁹, Marianne Camargo⁹, Andrew J. King⁹, Charlotte Jones-Burton⁹, Muh Geot Wong¹⁰

1. University of California Los Angeles; 2. University of Minnesota Division of Pediatric Nephrologytes; 3. Hallym University Sacred Heart Hospital; 4. Mountain Kidney and Hypertension Associates; 5. Royal Brisbane and Women's Hospital; 6. Tufts Medical Center; 7. Melbourne Renal Research Group; 8. Kidney Specialists of Southern Nevada; 9. Chinook Therapeutics Inctates; 10. Concord Repatriation General Hospital

Presented at ASN Kidney Week, November 3 2022, TH-PO497 (adapted from poster) Data cut-off October 19, 2022

Atrasentan is an investigational agent and has not been approved for any uses in patients.



Grant Funding:	Akebia, CareDx, Horizon
Consultant:	Alexion, Chinook, Horizon, Sanofi, Travere
PI on IgAN trials:	Alexion, Chinook, Novartis, Omeros, Otsuka, Travere, Vera, Visterra
Speaker Bureau:	Alexion, Bayer, Otsuka, Natera
Ownership:	Prolato Clinical Research Center, Medingenii Capital, Prosalus Capital




Background



IgA Nephropathy (IgAN)

- IgAN is the leading cause of primary glomerulonephritis, with a global incidence of 2.5 per 100,000 individuals per year¹
- Approximately 30-45% of IgAN patients progress to end-stage kidney disease (ESKD) over a period of 20-25 years²⁻⁵
- Proteinuria is strongly associated with kidney disease progression in IgAN^{2,6-7} and treatments that reduce proteinuria result in improved clinical outcomes in IgAN⁸⁻⁹




^{1.} Mcgrogan et al, 2011, NDT; 2. Reich et al, 2007, JASN; 3. Moriyama et al, 2014, PLOS ONE; 4. Rauen et al, 2020, Kidney Int; 5. Hastings et al, 2018, Kidney Int Rep; 6. Thompson et al, 2019, CJASN; 7. Barbour et al, 2019, JAMA Int Med; 8. Inker et al 2016 AJKD; 9. Inker et al, 2019, CJASN; 10. Tycova et al, 2018, Physiol Rev; 11. Kohan et al, 2014, Kidney Int; 12. Raina et al 2020 Kidney Dis; 13. Lehrke et al, 2001, JASN; 14. Zanatta et al, 2012, Renal Failure



AFFINITY Study Design





Key Eligibility Criteria: IgAN Cohort

- Biopsy-proven IgAN
- Maximally-tolerated and optimized dose of a RAS inhibitor (RASi) for ≥ 12 weeks prior to screening
- UPCR of 0.5 to < 1.0 g/g (56.5 mg/mmol to <113 mg/mmol) based on first morning void urine collected at screening
- eGFR \geq 30 mL/min/1.73 m²

Key Study Endpoints

- Change from baseline at week 12 in UPCR, based on average of two 24-hour collections
- Analysis based on an MMRM model of change from baseline in UPCR
- Adverse Event (AE) type, incidence, severity, seriousness and relatedness



Baseline and Safety



AFFINITY IgAN Cohort

- The AFFINITY IgAN cohort enrolled 20 patients with biopsy-confirmed IgAN
- All patients received concurrent, max-tolerated and optimized RASi at least 12 weeks prior to study and throughout the study period
- 70% of patients had baseline total urine protein >1 g/day despite optimized RASi treatment, representing an IgAN population at high risk for progression
- Mean treatment duration was 45 weeks (range 13-53 weeks) as of data cut-off October 19, 2022

Demographics, N=20		
Age, years, median (Q1,Q3)	45	(35, 58)
Women, <i>n</i> (%)	10	(50)
Race, <i>n</i> (%), Asian	9	(45)
White	9	(45)
Other	2	(10)
Baseline Characteristics	Med	ian (Q1, Q3)
Time from biopsy, years	3.9	(0.9, 11.8)
Blood pressure (mmHg) – Systolic	128	(116, 132)
– Diastolic	82	(77, 86)
BMI	26.2	(24.8, 29.2)
Brain Natriuretic Peptide (pg/mL)	12.5	(8.8, 42.0)
UPCR (g/g),	0.6	(0.5, 0.7)
First morning void at screening	0.0	(0.5, 0.77
24-hour UPCR (g/g)	0.8	(0.7, 1.1)
24-hour urine protein excretion (g/day)	1.2	(0.9, 1.5)
Urine protein excretion (g/day) ≥ 1, n (%)	14	(70)
eGFR (mL/min/1.73 m ²) §	46	(37, 74)
Concurrent RASi, n (%)	20	(100)
ACEi	8	(40)
ARB	12	(60)

[§] eGFR by CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration



Safety and Tolerability



 Atrasentan was generally well-tolerated with no treatment-related severe AEs to date

 One treatment-emergent AE (headache) led to study withdrawal


AE Category (N=20)		n (%)
Treatment emergent AEs	Subjects with any TEAE	16 (80)
(TEAEs), Severe AEs	Any TEAE occurring in N>1 subjects	
JEVELE ALS	COVID-19	7 (35)
	Dizziness	3 (15)
	Peripheral edema	2 (10)
	Headache	2 (10)
	Any Moderate TEAE	6 (30)
	Any Severe TEAE	O (O)
	TEAE leading to discontinuation (headache)	1 (5)
	Serious AE (traffic accident unrelated to study drug)	1 (5)
Treatment-related AEs	Any treatment-related AE	5 (25)
	Moderate related AEs	3 (15)
	Headache	1
	Creatinine increase/Renal impairment	1
	Peripheral edema	1



No Evidence of Significant Fluid Retention



- No increase in mean body weight
- No significant elevation in BNP (median change of 2.9 pg/mL at week 12)
- No meaningful change in systolic or diastolic BP
- Minimal acute change in eGFR (0.15 mL/min/1.73 m2 averaged across Weeks 2 and 6)




Data cut-off Oct. 19, 2022



Proteinuria Reduction in Patients with IgAN





Median (range) baseline protein excretion: 1.2 (0.9, 1.5) g/day

Proteinuria Reduction in Patients with IgAN


Treatment with atrasentan results in a durable and clinically meaningful proteinuria reduction in patients with IgAN receiving optimized standard-ofcare



Proteinuria Reduction in Patients with IgAN



79% of patients achieved >40% reduction in proteinuria at Week 24



Data cut-off Oct. 19, 2022





In this Phase 2 study of 20 patients with biopsy-proven IgAN, 70% of patients had baseline total urine protein >1 g/day despite optimized SOC treatment, representing an IgAN population at high risk for kidney disease progression

Treatment with atrasentan resulted in clinically meaningful reductions in proteinuria at weeks 6, 12 and 24

There were no meaningful changes in blood pressure nor acute eGFR changes, suggesting proteinuria reductions were not primarily due to hemodynamic effects of atrasentan

Atrasentan was generally well-tolerated with no treatment-related SAEs

There was no increase in BNP or mean bodyweight, suggesting minimal fluid retention

This analysis demonstrates that treatment with atrasentan results in **clinically meaningful proteinuria reductions** in patients with IgAN who remain at risk for progression with residual proteinuria despite optimized standard-of-care treatment







Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy

Jonathan Barratt¹, Laura Kooienga², Irfan Agha³, Hanna Thomas³, Biruh Workeneh⁴, Rangaraj Narayanan⁵, Bess Sorensen⁵, Brian S. Schwartz⁵, Andrew J. King⁵, Charlotte Jones-Burton⁵

1. University of Leicester, Leicester, Leicestershire, United Kingdom; 2. Colorado Kidney Care, Denver, CO, United States; 3. Dallas Renal Group, Dallas, TX, United States; 4. The University of Texas MD Anderson Cancer Center, Houston, TX, United States; 5. Chinook Therapeutics Inc, Seattle, WA, United States

Presented at ASN Kidney Week, November 2022, FR-PO659 (adapted from poster) Data cut-off October 13, 2022, unless otherwise noted

BION-1301 is an investigational agent and has not been approved for any uses in patients.

©2022 Chinook Therapeutics. All Rights Reserved.

Background: IgAN and the APRIL Pathway



IgA Nephropathy (IgAN)

- IgAN is the leading cause of primary glomerulonephritis, with approximately 2.5 per 100,000 individuals per year worldwide¹
- Approximately 30-45% of IgAN patients progress to end-stage kidney disease (ESKD) over a period of 20-25 years²⁻⁵
- Proteinuria is strongly associated with kidney disease progression in IgAN^{2,6-7} and treatments that reduce proteinuria result in improved clinical outcomes in IgAN⁸⁻⁹

The	A Proliferation Inducing Ligand (APRIL) is a TNF superfamily cytokine that drives IgA class switching and survival of IgA-secreting plasma cells ¹⁰
APRIL Pathway	Higher APRIL levels in patients with IgAN are correlated with higher pathogenic Gd-IgA1, proteinuria, and lower eGFR ¹¹⁻¹²
	APRIL increases Gd-IgA1 secretion from lymphocytes of patients with IgAN ¹¹




^{1.} Mcgrogan et al, 2011, NDT; 2. Reich et al, 2007, JASN; 3. Moriyama et al, 2014, PLOS ONE; 4. Rauen et al, 2020, Kidney Int; 5. Hastings et al, 2018, Kidney Int Rep; 6. Thompson et al, 2019, CJASN; 7. Barbour et al, 2019, JAMA Int Med; 8. Inker et al 2016 AJKD; 9. Inker et al, 2019, CJASN; 10. Suzuki et al, 2021, Sem Immunol; 11. Zhai et al, 2016, Medicine; 12. McCarthy et al, 2011, J Clin Invest



BION-1301* is a novel humanized monoclonal antibody that binds and blocks APRIL

- Potential disease-modifying approach by directly targeting the pathogenesis of IgAN
- BION-1301 was well-tolerated in patients with IgAN and resulted in depletion of Gd-IgA1 and sustained, clinically meaningful proteinuria reduction by 12 weeks of treatment¹³
- Phase 1 bioavailability study in healthy volunteers (HV) supports subcutaneous (SC) dosing¹⁴

BION-1301 in IgA Nephropathy





 ^{*} BION-1301 is an investigational drug that has not been approved by regulatory authorities. Efficacy and safety have not been established. There is no guarantee that it will become commercially available for the use(s) under investigation.
 13. Barratt et al. 2022. ERA: 14. Lo et al. 2020 ERA-EDTA





ADU-CL-19 (Part 3) is an ongoing phase 1/2 trial investigating BION-1301 in patients with IgAN (NCT03945318)

Cohort 1 (n=10)	450 mg Q2W IV \rightarrow 600 mg Q2W SC, up to 104 weeks [†]	Ongoing	
	[†] Patients transitio	ned to SC at ≥24 weeks	
Cohort 2 (n=30)	600 mg Q2W de novo SC, up to 104 weeks [∥]	Enrolling	
An optional 1-year treatment extension is available to both cohorts			
Objectives Key Eligibility Criteria, <u>Cohort 2</u>			
 Safety, tolerability, PK, immunogenicity, biomarker effects, and preliminary effect on proteinuria in patients with IgAN Biopsy-proven IgAN diagnosis within past 10 years Total protein excretion ≥ 0.5 g/24h OR UPCR ≥ 0.5 g/g based on 			
Proof of mechanism	24-hour urine collection at	screening	
 Proof of concept 	• eGFR ≥ 30 mL/min per 1.7	'3 m ²	

Proof of concept •

Explore dose/schedule, IV and SC administration •

• Stable/optimized dose of RASi for ≥ 3 months prior to screening (or intolerant to RASi)





Demographics and Baseline Characteristics

Demographics	Cohort 1 (n=10 ^{**}) 450 mg IV → 600mg SC	Cohort 2 (n=24) 600 mg de novo SC
Age, years, mean (min, max)	42 (27, 59)	40 (21, 74)
Sex, male, <i>n</i> (%)	9 (90)	15 (63)
Race, White, n (%) Asian, n (%) Black, n (%) Missing, n (%)	10 (100) 0 0 0	11 (46) 11 (46) 1 (4) 1 (4)
Ethnicity, Hispanic, n (%)	2 (20)	2 (8)
Country, US, n (%)	10 (100)	16 (67)
Baseline characteristics	Median (min, max)	Median (min, max)
Time from biopsy, years	2.1 (0.3, 7.7)	3.3 (0.1, 7.6)
Blood pressure (mmHg), Systolic Diastolic	127 (113, 133) 83 (69, 88)	127 (110, 147) 79 (57, 88)
eGFR (mL/min/1.73 m ²)§	69 (30, 122)	75 (37, 131)
24-hour urine protein excretion (g/day)	1.2 (0.7, 6.5)	1.0 (0.6, 2.7)
24-hour UPCR (g/g)	0.5 (0.4, 4.6)	0.8 (0.2, 3.2)
Renin-angiotensin system inhibitor use (%)	100%	100%

[§] eGFR by CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration ^{**} Two patients withdrew from study for reasons unrelated to study drug

Cohort 1 enrollment and treatment duration:

- 10 patients enrolled; 8 patients continued to SC
- Mean treatment duration of 64 weeks (range 0.1 to 106 weeks)
 - Mean treatment duration of 450 mg IV prior to transition to SC was 37 weeks
 - Mean treatment duration after transition to 600 mg SC was 40 weeks

Cohort 2 enrollment and treatment duration:

- 24 patients enrolled (enrolling up to 30 patients)
- Mean treatment duration of 17 weeks (range 2 to 30 weeks)





In Cohort 1 and Cohort 2:

- BION-1301 is generally well tolerated in IgAN patients, with no reported deaths, SAEs, or AEs leading to discontinuation of study drug to date
- All infections in patients with IgAN have been Grade 1 or 2 in severity and only one infection, which was Grade 1 in severity, was assessed as treatment-related
- Injection site reactions have all been Grade 1 or Grade 2 in severity
- IgG level below the study defined threshold (< 3 g/L) occurred in one patient in Cohort 1, requiring protocol-mandated withholding of study drug. There have been no infections reported in this patient

AE Category (I	N=34)	n (%)
Treatment	Patients with any TEAE	23 (67.6)
emergent AEs (TEAEs)	Patients with Infection TEAE (Grades 1 or 2)	17(50.0)
	Infection TEAE occurring in N>1 patient	
	COVID-19	8 (23.5)
	Upper Respiratory Tract Infection	3 (8.8)
	Asymptomatic COVID-19	2 (5.9)
	Sinusitis	2 (5.9)
	Urinary Tract Infection	2 (5.9)
Treatment-	Patients with any treatment-related AE	8 (23.5)
related AEs	Related AEs occurring in N>1 patient	
	Fatigue	3 (8.8)
	Injection site erythema	3 (8.8)




Pharmacokinetics



- Low inter-individual variability in BION-1301 serum concentrations following IV and SC administrations
- Trough concentrations of BION-1301 following 600 mg SC Q2W (Cohort 2) are consistent with trough concentrations observed following 450 mg IV Q2W (Cohort 1)
- No anti-drug antibodies observed in patients with IgAN to date

BION-1301 Serum Concentrations




Mean (± SD) BION-1301 serum concentrations following IV (Cohort 1) or SC (Cohort 2) administration Q2W[‡]. Data points after Day 7 are trough concentrations.

Data cut-off Sep 30, 2022



BION-1301 Results in Rapid and Durable Reduction in IgA and Gd-IgA1





Mean Gd-IgA1 are not available at week 100



Reductions in IgM, and to a Lesser Extent IgG, Were Also Observed



% Change from Baseline **Ig**M (Mean ± SE) Data cut-off Oct. 13, 2022 10% 0% -10% -Cohort 1 -20% -Cohort 2 -30% -40% -50% -60% -70% -80% -90% -100% Wk 4 81216202428 52 76 88 64 100 40 8 8 8 8 2 5 6 3 Co 1. n= 8 7 7 4 2318151010 9 3 Co 2. n=

lgG (Mean ± SE) Data cut-off Oct. 13, 2022 10% 0% -10% -20% -30% -40% -50% -60% Cohort 1 -70% ---Cohort 2 -80% Wk 4 81216202428 40 52 76 88 100 64 8888256 7 7 4 3 2 Co 1. n= 8 Co 2, n= 2318151010 9 3

% Change from Baseline

Mean IgM are not available at week 100

Data cut-off Oct. 13, 2022



BION-1301 Treatment Results in Sustained, Clinically Meaningful Proteinuria Reductions



% Reduction **UPCR** (Geometric Mean ± SE) Data cut-off Oct. 13, 2022 10% 0% Cohort 1 -10% ---Cohort 2 -20% -30.4% -30% -40% -28.7% -48.8% -50% -66.9% -67.4% -71.0% -60% -53.8% -70% -80% -90% -100% Wk 12 24 52 76 100 4 Co 1. n= 8 8 8 4 7 2 Co 2. n= 23 15 9

Median (range) baseline protein excretion: Cohort 1, 1.2 (0.7, 6.5) g/day ; Cohort 2, 1.0 (0.6, 2.7) g/day

Cohort 1 (IV \rightarrow SC):

- Clinically meaningful reductions in UPCR from baseline were seen in patients with IgAN across a wide range of baseline proteinuria levels by Week 12
- UPCR continued to decline through one year and then was maintained through two years, providing evidence of sustained efficacy
- Among patients with available data up to Week 52, 7/8 patients demonstrated a greater than 50% reduction in UPCR from baseline at Week 52

Cohort 2 (de novo SC):

• Mean reduction in UPCR of 53.8% at 24 weeks in Cohort 2 with de novo SC administration are consistent with those observed in Cohort 1



Conclusions



Interim Data Continues to Demonstrate Disease-Modifying Potential of BION-1301 in Patients with IgAN

- BION-1301 results in rapid and durable reductions in IgA and Gd-IgA1, the pathogenic IgA variant which drives IgAN pathogenesis
 - Reductions in IgM, and to a lesser extent IgG, were also observed
- BION-1301 is generally well-tolerated with no ADAs observed to-date in patients with IgAN
- BION-1301 results in clinically meaningful reductions in proteinuria in patients receiving optimized RASi
- Results are consistent across Cohort 1 (450 mg Q2W IV → 600 mg Q2W SC after 24 weeks) and Cohort 2 (600 mg Q2W SC)

These data provide proof-of-concept for the disease-modifying potential of BION-1301 to:

- ✓ deplete pathogenic Gd-IgA1 in patients with IgAN
- ✓ reduce proteinuria in patients with IgAN who remain at risk for progression with residual proteinuria despite optimized standard-of-care treatment

Clinical data to date supports BION-1301 (600mg SC Q2W) is well-tolerated and results in clinically meaningful proteinuria reductions to be further explored in phase 3





BION-1301 PI Perspective

Laura Kooienga, MD

Practicing Nephrologist and Director of Research at Colorado Kidney Care

Dr. Kooienga's Patients in Cohort 1

DEMOGRAPHICS	COHORT 1 (n=4) 450 mg IV → 600mg SC
Age, years, median (min, max)	47.5 (30, 58)
Sex, male, <i>n (%)</i>	4 (100)
Race, White, n (%) Asian, n (%) Black, n (%)	4 (100) 0 0
Ethnicity, Hispanic, <i>n</i> (%) Country, US, <i>n</i> (%)	4 (100)
BASELINE CHARACTERISTICS	Median (min, max)
BASELINE CHARACTERISTICS Time from biopsy, years	Median (min, max) 2.4 (0.13, 7.6)
Time from biopsy, years Blood pressure (mmHg), Systolic	2.4 (0.13, 7.6) 128 (118, 133)
Time from biopsy, years Blood pressure (mmHg), Systolic Diastolic	2.4 (0.13, 7.6) 128 (118, 133) 84.5 (84, 87)
Time from biopsy, years Blood pressure (mmHg), Systolic Diastolic eGFR (mL/min/1.73 m²)*	2.4 (0.13, 7.6) 128 (118, 133) 84.5 (84, 87) 70 (47, 122)

To date, Dr. Kooienga's 4 patients in Cohort 1 have been on treatment for 56 – 76 weeks

* eGFR by CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration, n=4



Dr. Kooienga's Patients in Cohort 2

DEMOGRAPHICS	COHORT 2 (n=6) 600 mg de novo SC
Age, years, median (min, max)	37 (27, 56)
Sex, male, <i>n (%)</i>	5 (83.33)
Race, White, <i>n</i> (%) Asian, <i>n</i> (%) Black, <i>n</i> (%)	4 (66.67) 2 (33.33) 0
Ethnicity, Hispanic, <i>n</i> (%)	0
Country, US, <i>n</i> (%)	6 (100)
BASELINE CHARACTERISTICS	Median (min, max)
BASELINE CHARACTERISTICS Time from biopsy, years	Median (min, max) 4.1 (0.67, 7.95)
Time from biopsy, years Blood pressure (mmHg), Systolic	4.1 (0.67, 7.95) 128.5 (118, 137)
Time from biopsy, years Blood pressure (mmHg), Systolic Diastolic	4.1 (0.67, 7.95) 128.5 (118, 137) 84.5 (72, 88)
Time from biopsy, years Blood pressure (mmHg), Systolic Diastolic eGFR (mL/min/1.73 m²)*	4.1 (0.67, 7.95) 128.5 (118, 137) 84.5 (72, 88) 58.5 (49, 75)

* eGFR by CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration, n=5

To date, Dr. Kooienga's 6 patients in Cohort 2 have been on treatment for 1 – 34 weeks



Dr. Kooienga's Clinical Experience with BION-1301

- Very positive experience with BION-1301 phase 1/2 study to date
- All of Dr. Kooienga's patients enrolled in Cohorts 1 and 2 have:
 - ✓ Tolerated BION-1301 well
 - ✓ Had clinically meaningful reductions in proteinuria as of their most recent visit
 - ✓ Tolerated subcutaneous injections well
 - ✓ Had no concerns around dosing frequency or subcutaneous delivery
 - ✓ Been highly motivated, engaged and committed to study







Preclinical Efficacy of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxalurias

Jennifer Cox¹, Marc-Olivier Boily¹, Alex Caron¹, Oliver Chong¹, Jim Ding¹, Samuel Gaudreault¹, Robert Gomez¹, John Knight², Jay Kuo¹, Jeff Lester¹, Xingsheng Li², W Todd Lowther³, Renata Oballa¹, David Powell¹, Hannah Sandford-Crane¹, Tao Sheng¹, Jayakumar Surendradoss¹, Vincent Tong¹, Joyce Wu¹, Andrew King¹

1. Chinook Therapeutics, 2. University of Alabama at Birmingham, 3. Wake Forest University


Presented at ASN Kidney Week, November 2022, FR-PO334 (adapted from presentation)

CHK-336 is an investigational agent and has not been approved for any uses in patients.



A

CHK-336 is a potent LDHA inhibitor in enzyme and hepatocyte assays across multiple species



Compound design and sub-nM potency guided by structural biology and X-ray crystallography of LDHA-inhibitor complexes

	Assay	CHK-336 IC ₅₀
	Human LDHA	0.2 nM
Enzyme	Mouse LDHA	0.3 nM
	Mouse Fresh Hepatocytes	52 nM
	Mouse Cryopreserved Hepatocytes	80 nM
Hepatocyte	Rat Cryopreserved Hepatocytes	130 nM
	Monkey Cryopreserved Hepatocytes	130 nM
	Human Cryopreserved Hepatocytes	121 nM
PH1 Hepatocyte	Mouse Agxt Knockdown Hepatocytes (Oxalate Production)	165 nM


- CHK-336 demonstrates potent inhibition of LDHA in enzyme assays (IC₅₀ = 0.2-0.3 nM) and primary hepatocyte assays across multiple species (IC₅₀ = 52-165 nM)
- CHK-336 also demonstrates tight LDHA binding with a very slow off-rate (hours-days)







Liver-targeted tissue distribution of CHK-336 and pharmacodynamic effect on the conversion of 13C2-glycolate into 13C2-oxalate



- CHK-336 exhibits a liver-targeted tissue distribution profile in mice, rats and monkey with high liver concentrations and low extra-hepatic tissue exposures
- Liver-targeted profile driven by OATP-mediated uptake results in high liver/plasma unbound ratios of 180-fold (rat) to 450-fold (monkey)
- Since LDHA catalyzes the final step of oxalate production from glycolate, a 13C2-glycolate stable isotope tracer was used to assess CHK-336 target engagement by measuring urinary excretion of 13C2-oxalate in Sprague Dawley rats
- Human PK predictions suggest CHK-336 has the potential to be a low, once-daily oral dose therapeutic in humans






C

34

CHK-336 produced significant and dose-dependent reductions in urinary oxalate in a PH1 mouse model




- CHK-336 was dosed orally, once-daily for 7 days in male Agxt KO mice and urinary oxalate concentrations were compared to a vehicle control group
- Low, oral, once-daily doses of CHK-336 significantly reduced urinary oxalate; majority of treated mice reached the normal range observed in wild-type mice
- CHK-336 had a more rapid onset of action and comparable magnitude of urinary oxalate reduction compared to a GO-targeting siRNA
- GO-siRNA was administered on day 0; Doses of 1, 3, and 6 mg/kg caused 56%, 75%, and 78% knockdown, respectively





D

CHK-336 significantly reduced urinary oxalate excretion in a genetic mouse model of PH2




CHK-336 was dosed orally, once-daily for 7 days at 25 mg/kg in male Grhpr KO mice and urinary oxalate concentrations were compared to a vehicle group



Conclusions



- CHK-336 is a potent LDHA inhibitor, with liver-targeted tissue distribution, that is efficacious in PH1 and PH2 mouse models of primary hyperoxaluria and has potential benefit in non-genetic hyperoxalurias caused by oxalate overproduction.
- The human safety and pharmacokinetic profiles of CHK-336 are currently under investigation in a healthy volunteer SAD/MAD study (NCT05367661).
- Target engagement will be assessed in humans using a novel stable isotope glycolate tracer approach (depicted below).



CHK-336 is a first-in-class oral LDHA inhibitor with the potential to treat all subtypes of primary hyperoxaluria as well as other disorders arising from oxalate overproduction







Single Nuclei RNAseq Reveals Cell-type Specific Responses to Disease and Enalapril in the gddY Mouse Model of IgAN

N. Eric Olson¹, Mark McConnell¹, Phillip J. McCown², Edgar A. Otto², Viji Nair², Marvin Gunawan¹, Sean Eddy², Jennifer H. Cox¹, Matthias Kretzler¹, Toshiki Kano³, Yusuke Suzuki³, Andrew J. King¹

1. Chinook Therapeutics Inc, Seattle, WA, United States; 2. University of Michigan, Ann Arbor, MI, United States; 3. Juntendo University Faculty of Medicine, Tokyo, Japan

Disclosures: N. E. Olson, Mark McConnell, Marvin Gunawan, Jennifer H. Cox, Matthias Kretzler, Andrew J. King - Chinook Therapeutics, Employed, Equity


Presented at ASN Kidney Week, November 2022, FR-PO659 (adapted from presentation)

Atrasentan is an investigational agent and has not been approved for any uses in patients.

©2022 Chinook Therapeutics. All Rights Reserved.

Cellular Composition





A Seurat clusters at resolution 0.3 generated 26 clusters'

- B Cell types were annotated using azimuth level 1 annotation which was supplemented with mesangial cells from azimuth level 3 annotation. Additionally, failed repair proximal tubular epithelial cells (FR PTEC) were annotated using the approach described in Figure 2.
- C Number of nuclei for each cell group by treatment. The majority of kidney cell types have well over 100 nuclei per treatment group, **providing good coverage** of the tubulointerstitial and glomerular compartments.

С	Control IgAN				
_	Vehicle	Vehicle	Atrasentan	ACEi	Total
ATL	313	160	126	165	764
CNT	1,615	2,291	2,158	2,472	8,536
DCT	2,953	3,170	3,753	3,480	13,356
DTL	2,539	2,269	2,205	2,681	9,694
ENDO	5,267	7,874	8,408	9,744	31,293
FIB	3,291	5,780	4,950	6,915	20,936
FR PTEC	278	1,564	971	1,648	4,461
IC	771	886	899	983	3,539
IMM	42	650	380	490	1,562
MES	195	378	366	721	1,660
PC	2,432	1,698	1,418	1,929	7,477
PEC	509	765	737	1,005	3,016
POD	2,248	1,334	1,656	2,310	7,548
PT	8,308	10,768	15,287	15,356	49,719
SCH	74	189	132	322	717
TAL	10,120	7,785	7,830	9,550	35,285
VSM_P	667	1,435	1,278	2,649	6,029
Total	41,622	48,996	52,554	62,420	205,592

ATL – Ascending thin limb; CNT – connecting tubule; DCT - distal convoluted tubule; DTL – descending thin limb; ENDO – endothelial; FIB – fibroblast; FR PTEC– failed repair proximal tubular epithelial cells; IC – intercalated; IMM – immune; MES – mesangial; PC – principal; PEC – parietal epithelial; POD –podocyte; PT – proximal tubule; SCH – schwann; TAL – thick ascending limb; VSM_P – vascular smooth muscle / pericyte




Results





FR PTEC are the most expanded kidney cell type in gddY



A FR PTEC are the most expanded kidney cell type in gddY compared to control, with ~4.7x the proportion of nuclei in gddY compared with control.

B FR PTEC have the largest number of differentially expressed genes (DEG), with 779 genes differentially expressed in gddY compared to control.




Results



3

FR PTEC are a source of chemokines and cytokines for immune cells and fibroblasts



Putative relationships for key FR PTEC ligands and corresponding receptors on potential target cell types

- Pro-inflammatory and profibrotic effects on fibroblasts may be mediated through Tnf and Tgfb2 signaling from FR PTEC.
- FR PTEC may play a key role in recruitment of immune cells through their expression of Ccl2.




Results





Comparison of pathway enrichments for atrasentan and ACEi treatment



- A In FR PTEC, gddY-induced DEGs were highly enriched for TNF-α signaling. Atrasentan treatment of gddY mice led to downregulation of genes that are enriched in the TNF-α hallmark.
- **B** In VSM/P cells, EMT was the primary hallmark increased in gddY. ACEi treatment had a modest effect on the increased expression of these genes.



Conclusions



Failed repair proximal tubular epithelial cells (FR PTEC) are a prominent feature of the gddY mouse model of IgAN	 This study identified a cluster of cells that scored highly for a FR PTEC signature and a TNF signature and were the most highly expanded kidney cell type in gddY. We propose that these cells represent FR PTEC, and that the expansion of these cells is a major characteristic of the gddY model and may play a major role in tubulointerstitial. inflammation and fibrosis and progressive kidney function loss. We have also found that FR PTEC are a key characteristic of CKD progression in human disease⁶.
Atrasentan and ACEi treatment resulted in different effects on gene expression	 Atrasentan induces the most gene expression changes in FR PTEC and these gene expression changes reverse pathogenic changes that are induced in the gddY disease model. ACEi treatment tends to induce new gene expression changes, most prominently in VSM/P.
Ongoing efforts to characterize gene	

Ongoing efforts to characterize gene expression associated with atrasentan response

• This atrasentan response signature is currently being evaluated in IgAN patient kidney biopsies and matched urine and serum samples are being screened for non-invasive surrogate biomarkers.

6. Bohnenpoll et al, Unsupervised Characterization of the NURTuRE Cohort Reveals Gene Expression and Tissue Remodeling Dynamics along a Synthetic CKD Progression Axis, ASN 2022 - SA-PO1011.









A Multi-Omics Approach to IgA Nephropathy Characterization in the NURTuRE Cohort Enables Precision-Based Treatment Approaches

<u>N. Eric Olson</u>, Jennifer Cox, I-Ju Lo, Seamus Ragan, Niklas Michel, Johannes Pospiech, Michaela Bayerlova, Simone Romoli, Taher Sathaliya, Tobias Bohnenpoll, Nikolas Stroth, Olivier Radresa, Andrew King, and Uwe Andag

FR-OR60, Glomerular Diseases: From Bench to Bedside [OR1300-1]


ASN Kidney Week, November 4, 2022


©2022 Chinook Therapeutics. All Rights Reserved.

Integration of Real-World Clinical, Morphological and Molecular Data



Project Aims:	 The aim of this project is to use a multi-omics approach to the characterization of IgAN in the NURTuRE cohort, integrating clinical, histological, transcriptomic and serum proteomic data to gain deeper insights into patient stratification and disease biology. These learnings will be applied to clinical studies evaluating atrasentan, an endothelin
-	receptor A antagonist, and BION-1301, an anti-APRIL antibody, for the treatment of IgAN.






https://www.nurturebiobank.org

Figure (lower left) adapted from Kidney Precision Medicine Project, accessed 4 May 2022, https://www.kpmp.org/about-kpmp

Serum Proteins Show Strong Relationship with Kidney Function





Highlight Select Targets with Significant Correlation Significance Threshold: | Correlation | >=0.3; -log10(adjusted p-value) >=1.3


- In the NUTURE IgAN cohort, serum proteins had the strongest relationship with eGFR
 - Endothelin 1 (EDN1) is strongly and significantly correlated with eGFR
 - APRIL (TNFSF13) is strongly & significantly correlated with eGFR and is also correlated with UPCR
 - BAFF (TNFSF13B) is not significantly correlated with eGFR, UACR or UPCR



A Preclinical Model Derived Atrasentan Response Signature^{*} is Correlated with Kidney Function




The atrasentan signature score from kidney biopsies is correlated with kidney function in the IgAN cohort



A 31-gene atrasentan response signature score was calculated using the gene expression data from kidney biopsies for the IgAN cohort. This score was correlated (spearman correlation test) with log10 eGFR, UACR and UPCR.

Increased atrasentan signature score is associated with tubular atrophy and interstitial fibrosis



A 31 gene atrasentan response signature derived from Failed Repair proximal tubule cells in the gddY IgAN model is significantly correlated with eGFR and UPCR in the IgAN cohort

The signature score is significantly higher in samples from subjects with an elevated T score

* See poster TH-PO419 for details

46



Future Plans



Future steps	 Urine proteomics will be performed on matched urine samples from the NURTuRE IgAN cohort and used to identify urine biomarker for atrasentan signature score Non-invasive surrogate biomarkers for the atrasentan response signature will be measured in atrasentan trials
Goals	 To validate non-invasive surrogate biomarker strategy that can be used in clinical trials for atrasentan in IgAN and other indications Assess the association of APRIL levels with baseline IgAN patient characteristics and kidney transcriptomics in support of patient stratification for BION-1301






Atrasentan Program Update

Potent and Selective Endothelin A Receptor (ET_A) Antagonist

Phase 3 ALIGN Trial Targeting patients with IgAN at high risk for disease progression



- ⊘ Global double-blind placebocontrolled study (~170 sites)
- ⊘ 320 patients, 1:1 randomization
- ⊘ Biopsy-proven IgAN
- Patients on maximally-tolerated, optimized and stable dose of RASi, or RASi intolerant
- ⊘ Proteinuria >1 g/day
- \odot eGFR >30 ml/min/1.73m²
- Primary endpoint 6-month proteinuria (accelerated approval)
- Secondary endpoint 2.5 year eGFR (full approval)



Top line

proteinuria data in


Q3 2023



eGFR endpoint

data

Additional Atrasentan Clinical Trials Underway



H1 2023 Phase 2 Study of Atrasentan + SGLT2i Combination in IgAN

- Data will support exploratory analysis from ALIGN atrasentan + SGLT2i combination strata
- Enroll IgAN patients at high risk for disease progression despite stable optimized RASi and stable SGLT2i
- · Randomize patients 1:1 to placebo/atrasentan
- Primary endpoint: change in UPCR from baseline to week 12
- Goal is for data to support future use and is not required for approval





BION-1301 Program Update

Anti-APRIL monoclonal antibody for patients with IgA nephropathy

BION-1301 Moving Forward

Plan to initiate pivotal trial in 2023, given strong clinical data and disease-modifying potential

Status	Cohort 1 in IgAN	450 mg IV → 600 mg SC q2w	Enrollment Completed
	Cohort 2 in IgAN	600 mg SC q2w	Enrolling up to 30 patients
BION-1301	Continues to demonstrate disease-modifying potential, with rapid and durable reductions in IgA and Gd-IgA1 and clinically meaningful proteinuria reductions in patients with IgAN across Cohort 1 (450 mg Q2W IV \rightarrow 600 mg Q2W SC after 24 weeks) and Cohort 2 (600 mg Q2W SC)		
Next Steps	 Align with global heal Conduct site and cour Initiate pivotal trial in 	ntry feasibility (ongoing)	




Proposed BION-1301 Phase 3 Trial Design

Plan to initiate pivotal trial in 2023, given strong clinical data and disease-modifying potential

Proposed Phase 3 Targeting IgAN Patients at Risk for Disease Progression

- ⊘ Global, double-blind, placebo-controlled
- \odot 1:1 randomization
- \odot Biopsy-proven IgAN
- Patients on maximally-tolerated, optimized and stable dose of RASi, or RASi intolerant
- ⊘ Proteinuria >1 g/day
- \odot eGFR >30 ml/min/1.73m2
- Primary endpoint 9-month proteinuria (accelerated approval)
- Secondary endpoint 2-year eGFR (full approval)



Trial design to be finalized following interactions with global health authorities





Closing Remarks

Catalysts

Program	Indication	Catalyst	H1 2022	H2 2022	2023
	IgA Nephropathy	Present data from IgAN patient cohort of AFFINITY	\checkmark	\checkmark	
Atrasentan		Initiate phase 2 trial in combination with SGLT2i in IgAN			
Alfasentan		Report topline proteinuria data from ALIGN in Q3 2023			
	Glomerular Diseases	Present additional data from other AFFINITY cohorts			
	IgA Nephropathy	Present phase 1/2 data from Cohort 1 in IgAN	\checkmark	\checkmark	
BION-1301		Present phase 1/2 data from Cohort 2 in IgAN		\checkmark	
		Initiate phase 3 trial in IgAN			
	Primary Hyperoxaluria	Initiate phase 1 study in healthy volunteers	\checkmark		
CHK-336		Report phase 1 healthy volunteer data and advance towards initiation of phase 2 POC trials for patients with primary and idiopathic hyperoxalurias			









CHINOOK THERAPEUTICS

©2022 Chinook Therapeutics. All Rights Reserved.